Edward James Olhava

Affiliations: 
2003 Harvard University, Cambridge, MA, United States 
Google:
"Edward Olhava"
Mean distance: 7.65
 
SNBCP

Parents

Sign in to add mentor
David A. Evans grad student 2003 Harvard
 (Catalytic asymmetric hetero -Diels -Alder reactions and applications in synthesis.)
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Waters NJ, Smith SA, Olhava EJ, et al. (2015) Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human. Cancer Chemotherapy and Pharmacology
Waters NJ, Daigle SR, Rehlaender BN, et al. (2015) Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target. Journal of Controlled Release : Official Journal of the Controlled Release Society
Kühn MW, Hadler MJ, Daigle SR, et al. (2015) MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition. Haematologica. 100: e190-3
Klaus CR, Iwanowicz D, Johnston D, et al. (2014) DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells. The Journal of Pharmacology and Experimental Therapeutics. 350: 646-56
Basavapathruni A, Olhava EJ, Daigle SR, et al. (2014) Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor. Biopharmaceutics & Drug Disposition. 35: 237-52
Daigle SR, Olhava EJ, Therkelsen CA, et al. (2013) Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 122: 1017-25
Deshpande AJ, Chen L, Fazio M, et al. (2013) Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood. 121: 2533-41
Chen L, Deshpande AJ, Banka D, et al. (2013) Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia. 27: 813-22
Knutson SK, Wigle TJ, Warholic NM, et al. (2012) A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nature Chemical Biology. 8: 890-6
Basavapathruni A, Jin L, Daigle SR, et al. (2012) Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L. Chemical Biology & Drug Design. 80: 971-80
See more...